Login to Your Account

Labrys Biologics Snags $31M Series A, CEO and Pfizer MAb

By Marie Powers
Staff Writer

Thursday, January 3, 2013
Labrys Biologics Inc. burst on the biotech scene with a $31 million Series A, a new president and CEO and the acquisition of a Phase II-ready anti-calcitonin gene-related peptide (CGRP) humanized monoclonal antibody (MAb) from Pfizer Inc. to treat chronic migraine.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription